Objective In this project we aim to develop a new delivery platform for allergy vaccines with a high efficacy and a high safety profile combining membrane fusion-mediated delivery and microneedle-based dermal delivery.Background: Within the ERC Starting Grant “Direct Drug Delivery”, I developed a method for the controlled fusion of liposomes with cells. A set of complementary peptide amphiphiles (coilK and coilE), able to form heterodimeric coiled coils, were shown to induce targeted and efficient fusion between two opposing membranes. More importantly, we have shown that this method of fusion can be applied to liposomes and to live cells. Since liposomes can be used as drug or vaccine carriers, this enables the direct delivery of these compounds into live cells. The Problem: Allergen-specific immunotherapy for treating allergies such as asthma is currently performed via chronic subcutaneous administration of allergen extracts to patients. Unfortunately, it requires monthly injections for several years to achieve the desired long-lasting immunological tolerance. These vaccinations are typically performed by intramuscular or subcutaneous injections, causing pain and stress. Therefore there is a need for a new and more efficient administration platform to achieve shorter, safer and more patient-friendly protocols.Our solution: Dermal delivery of vaccines offers a great potential, due to the large number of immune cells present in the skin. In order to increase the efficacy of current allergen-specific immunotherapy, it is our idea to use the membrane fusion heterodimeric coiled coil peptide pair to induce efficient cellular uptake and processing of a commercially used allergen (rBet v1) encapsulated in liposomes in order to increase its efficacy as an allergy vaccine. Fields of science medical and health sciencesclinical medicinepneumologyasthmanatural sciencesbiological sciencesbiochemistrybiomoleculesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesclinical medicineallergologymedical and health sciencesbasic medicineimmunologyimmunotherapy Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-PoC-2014 - ERC Proof of Concept Grant Call for proposal ERC-2014-PoC See other projects for this call Funding Scheme ERC-POC - Proof of Concept Grant Host institution UNIVERSITEIT LEIDEN Net EU contribution € 150 000,00 Address RAPENBURG 70 2311 EZ Leiden Netherlands See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 150 000,00 Beneficiaries (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSITEIT LEIDEN Netherlands Net EU contribution € 150 000,00 Address RAPENBURG 70 2311 EZ Leiden See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 150 000,00
